phase one study involving 35 women have revealed researchers have
developed a safe and effective chlamydia vaccine.
the study, two potential vaccines were given to the women, and their
bodies developed antibodies to the bacteria that causes chlamydia.
However, researchers say more work must be done before the vaccine is
First Step Is A Promising One
researcher and Center for Vaccine Research at Statens Serum Institute
Director of Infectious disease immunology Frank Follmann said having
an effective vaccine would have a huge impact on both public health
said the phase one trial shows that it’s the first hopeful step to
getting a vaccine. Follmann said the HPV vaccine success shows just
how effective vaccines are against STDs. He said the hope is to have
a chlamydia vaccine that may include a combination of them. The
study’s results are encouraging with the end goal to inoculate
young girls and boys before they start having sex.
expert, Fred Wyand, said the findings are promising. Wyand, a
spokesperson for the American Sexual Health Association, said it’s
been a challenge to develop a chlamydia vaccine, but there is reason
to hope that it can be possible someday thanks to the study.
said it’s important to remember that chlamydia can be easily
diagnosed, treated and cured through testing. The U.S. Centers for
Disease Control and Prevention recommends women 25 and older who are
sexually active should get yearly chlamydia testing.
the trial, women were randomly given one of the two vaccines or the
placebo. Of the women who received the vaccine, their body produced
antibodies to the disease. However, one vaccine – the CTH522:CAF01
– generated six times more antibodies than the other potential
said this is the formula that needs to be pursued. The results,
however, do not show a long-term protection from chlamydia or that it
will certainly protect someone from getting it.
most common side effects of the injection were pain and tenderness,
but they only lasted up to four days and were mild.
said research shows T-cells and antibodies can work together to
protect against chlamydia, but larger and long-term clinical trials
are necessary to determine if the vaccine can protect people from
becoming infected with the chlamydia bacteria.
most common STI is chlamydia with 131 people infected every year –
mostly in teens and young adults.
chlamydia infection also increases a person chances of contracting
other STIs like HIV and gonorrhea. Pregnant women with chlamydia can
suffer from a miscarriage, stillbirth or go into pre-term labor.
Women who are infected with the virus could experience pelvic
inflammatory disease that can lead to ectopic pregnancy, pelvic pain
women suffer more repercussions of a chlamydia infection, men can
also catch it too.
of North Carolina Professor of Pediatrics, microbiology and
immunology Dr. Toni Darville said the clinical chlamydia vaccine
testing is still in the early stages but does signify some optimism
for future generations.
important questions that stills need to be answered is can the
vaccine can protect women from damage in the upper reproductive tract
even if it’s unable to stop the infection totally. If immune cells
can obliterate the infection before it can get to the fallopian tubes
or oviducts, it may provide protection from chlamydia even if there
is an infection.
She also wondered if the vaccine would be permissible to both women and men, which would end up protecting women in the long run.